| Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. | |
| | |
MedLine Citation:
|
PMID: 20198559 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Dipeptidyl-peptidase (DPP)-4, which catalizes the degradation of the insulinotropic incretin glucagon-like-peptide (GLP)-1, and the DPP-4 like enzyme attractin are involved in activation of T-lymphocytes and monocytes. Recently, it has been demonstrated, that the risk for certain infections is increased in type 2 diabetic patients under DPP-4 inhibitor treatment. The aim of the present study was to examine the expression of DPP-4 and attractin in circulating blood monocytes of obese and type 2 diabetic subjects. Monocytes were isolated by CD14-antibody based magnetic cell sorting from blood samples of 17 lean controls, 20 obese, non-diabetic subjects and 19 obese patients with type 2 diabetes. FACS analysis was performed to test purity of the cell preparations. Expression was measured by multiplex RT-PCR on RNA-level. DPP-4 and attractin were detectable in human circulating monocytes with attractin being expressed at higher levels compared to DPP-4. Both enzymes were significantly higher expressed in circulating blood monocytes of obese subjects compared to lean controls. In contrast, type 2 diabetes did not significantly affect expression levels. Finally, neither DPP-4 nor attractin expression was altered by sitagliptin or insulin treatment. In conclusion, our data demonstrate, that expressions of DPP-4 and attractin in circulating blood monocytes of human subjects are influenced by metabolic abnormalities with obesity being an important factor. |
| | |
Authors:
|
M Laudes; F Oberhauser; D M Schulte; K Schilbach; S Freude; R Bilkovski; O Schulz; M Faust; W Krone |
Related Documents
:
|
2520259 - Cardiovascular disease in genotypes for obesity and diabetes. 22311219 - Hyperglycemia in nondiabetic patients during the acute phase of stroke. 17329619 - Omentin plasma levels and gene expression are decreased in obesity. 17077759 - Challenges and strategies: weight management in type 2 diabetes. 17679569 - Co-morbid conditions in overweight and obese airmen: trends and aeromedical implications. 17245359 - Rimonabant: more than an anti-obesity drug? 8300519 - Regulation of mannitol biosynthesis and degradation by cryptococcus neoformans. 11350189 - Analysis of linkage disequilibrium between polymorphisms in the kcnj9 gene with type 2 ... 1563539 - Elevated levels of paf-acether in blood of patients with type 1 diabetes mellitus. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-03-02 |
Journal Detail:
|
Title: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Volume: 118 ISSN: 1439-3646 ISO Abbreviation: Exp. Clin. Endocrinol. Diabetes Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-09-15 Completed Date: 2011-01-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9505926 Medline TA: Exp Clin Endocrinol Diabetes Country: Germany |
Other Details:
|
Languages: eng Pagination: 473-7 Citation Subset: IM |
Copyright Information:
|
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York. |
Affiliation:
|
Department of Internal Medicine II, University of Cologne, Germany. matthias.laudes@uk-koeln.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antigens, CD14
/
analysis Body Mass Index Diabetes Mellitus, Type 2 / blood*, drug therapy, enzymology Dipeptidyl Peptidase 4 / blood* Dipeptidyl-Peptidase IV Inhibitors / therapeutic use Female Glucagon-Like Peptide 1 / blood, metabolism Humans Hypoglycemic Agents / pharmacology, therapeutic use Insulin / therapeutic use Male Membrane Proteins / blood* Middle Aged Monocytes / enzymology* Obesity / blood*, enzymology Pyrazines / therapeutic use Triazoles / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/ATRN protein, human; 0/Antigens, CD14; 0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/Membrane Proteins; 0/Pyrazines; 0/Triazoles; 0/sitagliptin; 11061-68-0/Insulin; 89750-14-1/Glucagon-Like Peptide 1; EC 3.4.14.5/Dipeptidyl Peptidase 4 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of activin a in the human osteoblast cell cycle: a preliminary experimental in vitro study.
Next Document: Type-1 Diabetes Induces Depot-Specific Alterations in Adipocyte Diameter and Mass of Adipose Tissues...